Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and ...

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing therapies for rare diseases, finds itself at a critical juncture as it navigates regulatory challenges and ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Travere Therapeutics TVTX in the last three months. In the table below, you'll find a ...

Travere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an ...

New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (Nasdaq: TVTX) today ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.